MiNK Therapeutics Q3 net loss $5.1M; cash $6.4M; agenT-797 shows durable solid tumor benefit

MiNK Therapeutics, Inc.

2023-Q3 EPS reported -$0.50

Cash $6.4M at Sep 30, 2023, down from $19.6M at Dec 31, 2022; Q3 cash used in ops $4.2M.
Q3 net loss $5.1M ($0.15/sh); 9-month net loss $17M ($0.50/sh), vs $20.2M ($0.60/sh) year ago.
AgenT-797: >30% disease stabilization/biomarker response in heavily pretreated solid tumors; durable gastric cancer response.
Randomized Phase 2 trial of agenT-797 in 2L gastric cancer to launch this year, externally funded, led by MSKCC.
R&D expense down to $3.4M ($6.2M in Q3 2022) as company focuses iNKT platform and cGMP manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MiNK Therapeutics, Inc. reported third quarter 2023 results: net income $17 million, or $0.50 per share, EPS ($0.50).

Period: third quarter 2023
Net income: $17 million, or $0.50 per share
EPS: ($0.50)
Result: reported results

Exact text from the filing

Net loss for the nine-months ended September 30, 2023 was $17 million, or $0.50 per share, compared to net loss for the same period in 2022 of $20.2 million or $0.60 per share.

View on SEC.gov

Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-006910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.